ImmuCell Q4 preliminary sales dip

ImmuCell

08/01/2026 21:27

Overview

Animal health company's preliminary Q4 sales declined 1.6% yr/yr

Domestic sales rose 8.7%, while international sales fell 52.6%

Outlook

Company focuses on expanding First Defense capacity after pausing Re-Tain investment

ImmuCell plans manufacturing improvements to support First Defense growth targets

Result Drivers

TRI-SHIELD GROWTH - Tri-Shield sales increased by 41.3%, driven by new dairy and beef customers, according to CEO Olivier te Boekhorst

INTERNATIONAL SALES DECLINE - International sales fell 52.6% due to order timing, per CEO Olivier te Boekhorst

STRATEGIC SHIFT - Focus on First Defense after FDA issues with Re-Tain, resulting in a $2.9 mln write-down

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Product Sales
$7.60 mln


Press Release: ID:nGNX2gDkM2

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)